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Journey in Evolution of Nuclear Cardiology
Will There Be Another Quantum Leap With the F-18–Labeled Myocardial
Perfusion Tracers?
Vasken Dilsizian, MD,* Raymond Taillefer, MD†
Baltimore, Maryland; and Montréal, Quebec, Canada
The field of nuclear cardiac imaging has evolved from being rather subjective, more “art than a science,” to a
more objective, digital-based quantitative technique, providing insight into the physiological processes of
cardiovascular disorders andpredictingpatientoutcome. In amere4decadesof its clinical use, the technology
used to image myocardial perfusion has made quantum leaps from planar to single-photon emission com-
puted tomography (SPECT) and now to a more contemporary rapid SPECT, positron emission tomography
(PET), and hybrid SPECT-computed tomography (CT) and PET-CT techniques. Meanwhile, radiotracers have
flourished frompotassium-43and redbloodcell–taggedbloodpool imaging to thallium-201and technetium-
99m–labeledSPECTperfusion tracers alongwith rubidium-82, ammoniaN-13, andmore recently F-18fluorine-
labeled PET perfusion tracers. Concurrentwith this expansion is the introduction of newquantitativemethods
and software for image processing, evaluation, and data interpretation. Technical advances, particularly in
obtaining quantitative data, have led to a better understanding of the physiological mechanisms underlying
cardiovascular diseases beyond discrete epicardial coronary artery disease to coronary vasomotor function in
the early stages of the development of coronary atherosclerosis, hypertrophic cardiomyopathy, and dilated
nonischemic cardiomyopathy. Progress in the areas of molecular and hybrid imaging are equally important
areasofgrowth innuclear cardiology.However, thispaper focuseson thepast and futureofnuclearmyocardial
perfusion imaging and particularly perfusion tracers. (J AmColl Cardiol Img 2012;5:1269–84) © 2012 by the
American College of Cardiology Foundationp
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torHistorical Perspective of Radiotracer
Techniques and Instrumentation for the
Assessment of Myocardial Perfusion
The application of the radiotracer technique for
interrogating physiological processes and under-
standing cardiopulmonary circulation dates back
to the early 20th century. While studying radio-
isotopes of ionic potassium and rubidium in the
1950s, investigators were able to demonstrate
that uptake of these agents in the myocardium is
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brane (1). Because potassium is the major intra-
cellular cation in muscle, scientists concentrated
on developing intravenously injected ionic myo-
cardial perfusion tracers that have biological
properties similar to those of potassium for myo-
cardial imaging (2). Thallium-201 (201Tl) and
rubidium-82 (82Rb) are 2 such ionic myocardial
erfusion tracers with more favorable photon
nergy spectrum than potassium-43 and shorter
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1270physical half-lives. Thus, in 1975, 201Tl-chloride be-
ame the myocardial imaging tracer of choice for
linical studies to identify patients with anginal chest
ain and epicardial coronary artery narrowing (3–5),
nd 82Rb-chloride followed suit in 1990 (6–8).
Progress in the development of instrumentation
paralleled the clinical application of myocardial perfu-
sion tracers. Despite exciting advances in radiotracer
development, the spatial resolution of the scinti-
graphic instruments used to measure tracer concentra-
tion in the heart, lungs, and blood was limited. The
clinical feasibility of imaging the high-energy photons
of potassium 43 with a standard rectilinear scan-
ner and gamma camera was first described in 1973 by
Drs. Zaret and Strauss (Fig. 1) (2). The early applica-
tion of planar cameras in the heart resulted in a
2-dimensional representation of a 3-dimensional
structure, which can degrade and mask a
myocardial perfusion defect or regional
wall motion abnormality due to overlying
or underlying activities. The advent of
single-photon emission computed tomog-
raphy (SPECT) in the late 1970s and
positron emission tomography (PET) in
the 1980s dramatically changed the field
of nuclear cardiology, which became rec-
ognized as a separate discipline within
cardiology shortly thereafter. Noninvasive
assessment of myocardial perfusion is now
widely used and has become central for
detecting physiologically significant coro-
nary artery disease (CAD) and guiding
patient management. In the meantime,
there has been increasing interest in quan-
titative methods of myocardial perfusion
imaging that have contributed to the de-
velopment of more objective tests (9).
Such user-friendly and robust SPECT software has
played a critical role in the enhanced acceptance of
stress-rest nuclear myocardial perfusion studies by
the cardiology community worldwide.
SPECT and PET: Similarities and Differences
SPECT and PET use the same reconstruction
process but differ in the kind of instrumentation
and range of radiopharmaceuticals used. Because
tomographic images offer a 3-dimensional distribu-
tion of activity, the target is separated from back-
ground, resulting in improved image contrast, lo-
calization, and quantification. SPECT permits
se
w
rve
l
ssionnoninvasive evaluation of myocardial blood flow r(MBF) by extractable tracers such as 201Tl- and
echnetium-99m (99mTc)–labeled perfusion tracers.
ET, on the other hand, permits noninvasive as-
essment of MBF, function, and metabolism using
hysiological substrates prepared with positron-
mitting isotopes such as carbon, oxygen, nitrogen,
nd fluorine. Radioisotopes commonly used with
PECT emit gamma rays of varying energies and
ave relatively longer physical half-lives than those
sed with PET. Although clinically useful, esti-
ates of relative MBF by SPECT are significantly
ffected by attenuation artifacts. Positron-emitting
adioisotopes commonly used with PET emit 2
amma rays, 511 keV each. Because the gamma
ays are perfectly collinear (discharged at 180° to
ach other) and travel in opposite directions, the
ET detectors can be programmed to register only
vents with temporal coincidence of photons that
trike directly at opposing detectors. This results in
mproved spatial (4 to 6 mm) resolution compared
ith SPECT as well as temporal resolution. The
igher temporal resolution of PET is also explained
y the fact that the imaging device is stationary
ompared with the rotating imaging gantry for
PECT. Moreover, the PET system is more sen-
itive than a SPECT system (higher count rate) and
rovides the possibility of attenuation correction.
orrection for photon attenuation is a ”must” for
ET because of the more dramatic effect of photon
ttenuation on the PET images. Two photons per
vent are more sensitive to attenuation than only 1
or SPECT. The result of these advantages with
ET is the potential for quantitation of tracer
oncentration in absolute units. Quantification of
BF may provide diagnostic and prognostic infor-
ation earlier than visual interpretation of relative
adiotracer uptake, which is a fundamental disad-
antage of the conventional SPECT technique.
hese limitations of SPECT technology and the
equirements for absolute MBF assessment led to
he development of better rapid SPECT technology
n recent years. This includes a change from the
onventional Anger scintillation camera, which
onverts the gamma rays to light photons via
odium iodide scintillation detectors to a series of
mall-size, pixilated solid-state detector columns
ith cadmium zinc telluride or Cesium Iodide
sI(Tl) crystals, which provide considerably more
nformation for each detected gamma ray (10).
ompared with the conventional SPECT cameras,
he high-speed SPECT systems can provide as
uch as an 8-fold increase in count rates, therebyA B B R E V I A T I O N S
A N D A C R O N YM S
CAD coronary artery disea
FDA U.S. Food and Drug
Administration
LV left ventricular
MBFmyocardial blood flo
MFRmyocardial flow rese
N-NOET N-ethoxy-N-ethy
dithiocarbamato-nitrito
PET positron emission
tomography
82Rb rubidium 82
PECT single-photon emi
omputed tomography
201Tl thallium 201educing imaging times significantly from 14 to 15
) (Th
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1271min with a conventional Anger camera to 5 to 6
min with the newer solid-state cameras, while
achieving a 2-fold increase in spatial resolution
from 9 to 12 mm for Anger cameras to 4.3 to 4.9
mm for cadmium zinc telluride cameras (11).
Quantification of MBF, Flow Reserve,
and Relative Radiotracer Content
An important driver for cardiac PET comes from a
new health care trend in cardiovascular medicine
that suggests a paradigm shift in cardiovascular
medicine from detection and treatment of CAD to
prediction and prevention. Current clinical applica-
tion of myocardial perfusion SPECT is focused
predominantly on the identification of isolated le-
sions, which can be treated by coronary revascular-
ization. As aggressive medical therapy and/or pre-
vention become effective alternative treatment
options for CAD (12), the need arises to tailor the
medication to the individual needs of patients. This
makes quantitative measures of MBF with PET
Figure 1. Stress Myocardial Perfusion Imaging With Potassium-
(A) A rectilinear scanner used to record potassium-43 myocardial p
ease injected at stress in the anterior and left anterior oblique (LAO
Anterior views of a patient with signiﬁcant right coronary artery (RC
stress (C). (D) Photograph circa 1972, of Dr. H. William Strauss (Nuc
the back of Dr. Robert Stenson (Cardiology). Dr. Barry Zaret (Cardiolog
registration form. Adapted in part, with permission from Zaret et al. (2very attractive because PET can assess coronaryendothelial dysfunction and allows for a reliable
comparison between a baseline study and follow-up
studies, which is an important step for personalized
medicine. By acquiring dynamic, gated myocardial
perfusion data, PET studies provide insight into
impairment of regional MBF due to epicardial
coronary artery stenosis, diffuse epicardial vessel
disease, microvascular disease, and/or endothelial
dysfunction.
Conventional SPECT approaches identify flow-
limiting coronary artery narrowing by delineating
the relative spatial distribution of radiotracer con-
tent in the left ventricular (LV) myocardium during
stress and again at rest. Although this approach has
been clinically useful for identifying end-stage
CAD, it does not permit comparisons of absolute
regional MBF at rest and during stress, in the same
region, quantitatively. Furthermore, SPECT may
underestimate balanced reduction in MBF or dif-
fuse nonocclusive luminal coronary artery narrow-
ing. Multivessel CAD, resulting in equally re-
stricted flow in all coronary distributions, could be
sion images recorded at rest and stress. Images of a patient without
ws (B), with a diagram of the coronary arteries superimposed on an
tenosis injected at rest and at stress with the electrocardiogram reco
Medicine, left) ﬁlling out the registration form for the Society of Air F
next to Dr. Stenson, and Dr. Ralph Reynolds (with pipe, Hematology) is
e photograph at bottom is original.)43
erfu coronary artery dis-
) vie outline of the scan.
A) s rded at rest and
lear orce Physicians, using
y) is also completing hisinterpreted as a normal study in terms of relative
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1272radiotracer content when in fact absolute MBF in
all myocardial regions is decreased (Fig. 2) (13).
imilarly, the myocardial region with the highest
adiotracer uptake (usually assigned as the reference
egion) that is presumed to be supplied by a normal
oronary artery may have less severe flow-limiting
isease or disease that is not yet flow limiting. Beyond
dentifying flow-limited coronary artery narrowing,
uantitative regional MBF and myocardial flow reserve
MFR) assessment with PET may identify early, pre-
linical atherosclerosis even before hemodynamically sig-
ificant stenosis develops. Because the majority of acute
Polar Map of Myocardial Tracer Uptake During Adenosine
on in a Patient With CAD
e distribution of the radiotracer (as would be the case with single-
ission computed tomography studies) suggests a single-vessel
the territory of the left anterior descending artery (LAD).
itative assessment of regional myocardial ﬂow reserve with 13N-
positron emission tomography. In a vascular territory without
coronary artery stenosis, normal myocardial ﬂow reserve is
tely 3 ml/min/g. As such, quantitative myocardial blood ﬂow
t identiﬁes abnormal ﬂow reserve in all 3 vascular territories in
t: 1.37 ml/min/g in the LAD territory, 1.65 ml/min/g in the left
artery (LCX) territory, and 1.91 ml/min/g in the right coronary
A) territory. The clinical implication for the presumed diagnosis
l coronary artery disease (CAD) on the evaluation of relative
l radiotracer uptake versus 3-vessel CAD on quantitative
t of myocardial ﬂow reserve is important and not inconse-
oreover, follow-up polar maps (C, D) acquired 1 year after
erapy with pravastatin show signiﬁcant improvement in myocardial
e in all 3 vascular territories compared with baseline values (A, B).
of the stress-induced defect decreased from 51% of the LAD vascu-
to only 3%. Moreover, there is increased normalization in myocar-
serve in the LCX and RCA vascular territories, which could only be
n quantitative measurements of myocardial blood ﬂow (D) but not
luation of the relative radiotracer uptake (C). Adapted, with permis-o
Schelbert and Oxilia-Estigarribia (13).oronary events originate in coronary arteries without
istinct angiographic stenosis, identification of pre-
linical atherosclerosis could prove clinically important.
he latter may provide a strong rationale for aggressive
edical and/or therapeutic interventions in such patients
efore advanced CAD ensues. A main advantage of
edical therapy is that beyond its beneficial effect on the
solated coronary artery lesion, its systemic effect on all
essels (e.g., coronary, carotid, peripheral) may prevent
urther progression of atherosclerosis.
Coronary flow reserve for the noninvasive assess-
ent of physiological stenosis severity was first
escribed in 1974 by Dr. K. Lance Gould (14),
nitially using reactive or contrast hyperemia, then
ith the first dipyridamole vasodilator imaging in
hronically instrumented animals in collaboration
ith Dr. Heinrich R. Schelbert and the UCLA
nvestigators. This joint work led to the Georg von
evesy Prize in 1978 for identifying mild coronary
tenosis using 13N-ammonia (Fig. 3) (14–16). In
1982, Dr. Schelbert reported on the first clinical
study of cyclotron-produced 13N-ammonia dipyri-
amole myocardial perfusion PET in human sub-
ects, which showed high sensitivity and specificity
or detecting CAD (Fig. 4) (17). This was followed
y the introduction of another PET myocardial
erfusion tracer, 82Rb, which is generator produced
ith biological properties similar to potassium and
201Tl (18,19). The relationship between regional
82Rb PET myocardial uptake, flow measured by
microspheres, and absolute reduction of cation up-
take in ischemia was first reported in experimental
animals in 1982 by Dr. Andrew Selwyn along with
the clinical application of 82Rb PET in volunteers
and patients, at rest and again at 0, 10, and 20 min
after a symptom-limited maximal exercise per-
formed supine using a bicycle ergometer (18). The
technique was then applied in a subsequent paper
by Dr. Deanfield et al. (19) to document myocardial
ischemia during both symptomatic and asymptom-
atic ST-segment depression in patients with stable
angina. In 1986, the first large clinical trial of
pharmacological coronary vasodilation 82Rb PET
as reported by Gould et al. for the noninvasive
etection of CAD (5,6). In the ensuing years, the
ranslational concepts of stenosis flow reserve, frac-
ional flow reserve, and imaging reversal of CAD
ere established in the literature (20–25). The
linical integration of quantitative rest and maxi-
um MBF and absolute and relative MFR, as-
essed by PET, can now be used to guide invasive
rocedures and medical lifestyle treatment and theirFigure 2.
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ammonia
signiﬁcant
approxima
assessmen
this patien
circumﬂex
artery (RC
of 1-vesse
myocardia
assessmen
quential. M
medical th
ﬂow reserv
The extent
lar territory
dial ﬂow re
detected o
on the evautcomes (25–29). Such quantitative PET flow
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 2 , 2 0 1 2
D E C E M B E R 2 0 1 2 : 1 2 6 9 – 8 4
Dilsizian and Taillefer
The Past and Future of Nuclear Cardiology
1273Figure 3. Progress From the Earliest Coronary Flow Reserve Recordings to Current PET MBF Quantitative Measurements
One of the earliest coronary ﬂow meter recordings in 1974 is shown (A) along with a photograph of Dr. K. Lance Gould (B).
(C) A very early 82Rb image from 1984 on the ﬁrst whole-heart multiring positron emission tomography scanner designed and built
in Houston, Texas. (D) The proposal of a coronary ﬂow reserve ﬂow map in 2012, based on maximum ﬂow in healthy volunteers
and the low-ﬂow ischemic ﬂow threshold causing angina and electrocardiographic ST-segment changes. Adapted in part, with per-
mission from Gould et al. (14) and Johnson and Gould (23).
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1274measurements have been used to demonstrate im-
provement in endothelial dysfunction and myocar-
dial ischemia in patients with advanced CAD after
medical treatment, vitamin C, and a regular exercise
program (26–32).
Prognostic value of quantitative MBF measurements
beyond relative regional perfusion defects in patients
with suspected CAD and without CAD. Beyond the
ell-established diagnostic value of myocardial per-
usion with PET, emerging data suggest the incre-
ental prognostic value of absolute MBF and MFR
erimental and Clinical Dynamic N-13 Ammonia PET Images
onia images obtained in a dog experiment with the second-generatio
ugh the right and left ventricles is shown (ﬁrst to second rows) follo
onia input function and myocardial tissue response to it, generated
n a young healthy volunteer. Based on the known tissue tracer kinet
rm the base of quantitative estimates of myocardial blood ﬂow. (C) T
th an angiographically documented proximal left anterior descending
uring a 1979 meeting in Germany after the ﬁrst positron emission to
left to right: Dr. Heinrich R. Schelbert, UCLA, Los Angeles, California
x Planck Institute for Circulation Research, Bad Nauheim, Germany; an patients with suspected CAD. Using 13N- pmmonia PET, an abnormal global MFR 2.0
rather than regional) was found to be indepen-
ently associated with a higher annual event rate for
ajor adverse cardiac events and cardiac death over
years compared with normal MFR (33). In
ubjects with abnormal perfusion, MFR remained
redictive throughout the 10-year follow-up. Sub-
equent papers from different institutions confirmed
he incremental prognostic value of MFR in the
isual assessment of regional radiotracer uptake
sing 82Rb PET (Fig. 5) (34–37). Among diabetic
ommercial positron emission tomography system. The initial
by radiotracer uptake in the myocardium. (B) Time activity curves
regions of interest assigned to the left ventricular blood pool
f 13N-ammonia, as deﬁned earlier in animal experimental studies,
ﬁrst 13N-ammonia rest (control) and hyperemia stress perfusion
ery stenosis and a severe stress-induced perfusion defect. (D) A
raphy 13N-ammonia dog study was done and the ﬁrst patient
. Paul Cannon, Columbia University, New York, New York; Dr.
r. K. Lance Gould, University of Texas, Houston, Texas.Figure 4. Earliest Exp
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1275cardiac death in those with impaired MFR compa-
rable to that of patients with previous CAD,
whereas among diabetic patients with preserved
MFR, cardiac mortality rates were comparable to
those of nondiabetic patients (38).
Recent studies suggest that the degree of vasodi-
lator capacity of the coronary circulation and mi-
crovascular dysfunction are predictive of future
cardiovascular outcome in patients with hypertro-
phic cardiomyopathy or with nonischemic dilated
cardiomyopathy (39,40). As pharmacologically in-
duced hyperemic MBF increases reflect smooth mus-
cle cell function of the coronary arteriolar vessels and
up to 25% flow-mediated endothelium-related vaso-
dilatory effects, it is also frequently reported as the
“total integrated coronary circulatory function.” Thus,
the flow response to vasodilator stress reflects the
functional and structural integrity of the coronary
circulation, including endothelial and vascular smooth
muscle function at the level of the large epicardial
conduit and the microvessels. In patients with
hypertrophic cardiomyopathy who underwent di-
pyridamole MBF PET studies and were followed
for an average of 8 years, the overall cumulative
survival and survival free of an unfavorable outcome
were associated with the level of hyperemic MBF
achieved during pharmacological vasodilation (39).
Similar results were attained among patients with
idiopathic dilated cardiomyopathy who underwent
dipyridamole MBF PET studies and were followed
for a mean of 3 to 4 years. Impaired MFR on PET
was associated with an increase in relative risk of
death or progression of heart failure of 3.5 times
over other more common clinical and functional
variables (40).
Is PET and absolute MBF quantiﬁcation ready for
everyday clinical application? Although assessment
f absolute MBF with PET has become an indis-
ensable tool in cardiac research, it remains unde-
used in clinical practice. Not only are the PET
ameras expensive, but radiotracers, which require
ither a cyclotron or an expensive generator for
sotope production, are quite expensive to maintain
nless maintenance costs are shared with other
ubspecialties, such as oncology. Beyond the ex-
ense of the technology and radiotracers, the as-
essment of absolute MBF is technically challeng-
ng. Published absolute MBF thresholds in the
iterature for differentiating normal from abnormal
yocardium are variable. The technical challenges
hat affect the uniformity of absolute MBF mea-
urements are multifactorial and dependent on: 1)
he radiotracer; 2) PET hardware; and 3) PET ooftware. Absolute quantification of MBF requires
hat the radiotracer uptake in the myocardium be
roportional to regional MBFs and increase linearly
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Figure 5. Prognostic Value of MFR by Stress 82Rb PET
In a large cohort of patients referred for assessment of myocardial
with 82Rb positron emission tomography (PET), the added and inde
prognostic value of myocardial ﬂow reserve (MFR) was determined
the conventional relative myocardium radiotracer uptake on attenu
corrected PET images. Patients with impaired 82Rb MFR had a high
dence of hard and major adverse cardiac events (MACE) (cardiac de
nonfatal myocardial infarction, late revascularization, or hospitalizat
cardiac reasons) at approximately 1-year follow-up. In the multivari
model analysis, 82Rb MFR was an independent predictor of hard ev
and MACE (B) over the summed stress score (SSS). (C) MACE within
groups of SSS for different levels of MFR is shown. At any level of S
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1276important criteria, 13N-ammonia and 82Rb radio-
racers do not, as they demonstrate “roll-off” at high
BF levels that deviate from the line of identity.
he implications of this are that at higher flow
evels, relative myocardial tracer uptake may under-
stimate absolute MBF, and thereby underlying
AD. Beyond the radiotracers, the PET camera
rystals must have high-count-rate performance
nd the hardware must have high spatial and
emporal resolution to be able to detect changes in
he radiopharmaceutical signal over time using dy-
amic acquisition. PET detector dead-time issues
ay require a decrease in the administered radio-
racer dose and protocol optimization depending on
he count-rate characteristics of the particular sys-
em (41). The software should apply an appropriate
racer kinetic model and should be systematically
alidated to extract quantitative information from
he dynamically acquired radiotracer kinetic signal
n a highly reproducible manner. Ultimately, the
roader widespread clinical application of absolute
BF will rely on the commercial availability of
obust U.S. Food and Drug Administration
FDA)–approved software.
Progress in the Development of
Novel Radiopharmaceuticals and
Myocardial Perfusion Tracers
Transition from 201Tl- to 99mTc-labeled SPECT myocardial
erfusion tracers. After the discovery of the element
Tc and 99mTc in 1938, and the molybdenum
9/99mTc generator in the early 1950s, the field of
uclear medicine gained tremendous growth. The
nitial kinetics of myocardial perfusion agents is
ependent on coronary flow, and subsequent kinet-
cs is dependent on diffusion or active transport of
he tracer into cardiac myocytes followed by clear-
nce from the cells. 201Tl is one of the best of the
soluble myocardial perfusion agents for measuring
regional MBF because it has a blood clearance
half-time of 30 s and a first-pass extraction in the
myocardium 88% at rest (42), which results in
high sensitivity, specificity, and diagnostic accuracy
of myocardial perfusion imaging with both exercise
and pharmacological vasodilators (43,44). Beyond
detection of CAD, the clinical value of 201Tl extends
to the assessment of myocardial viability in patients
with LV dysfunction (45). However, some of the
physical characteristics of this widely used radionu-
clide, such as the low energy of its predominant
photon and long physical and biological half-lives
with a resultant effective half-life of 56 h are not asavorable for scintillation camera imaging. In the late
970s and early 1980s, many investigators attempted
o develop a myocardial perfusion imaging agent
abeled with 99mTc to circumvent these limitations of
201Tl (Table 1). 99mTc-labeled SPECT myocardial
erfusion tracers were introduced for clinical use in the
990s (46,47).
Despite the excellent physiological characteristics
f 201Tl for myocardial perfusion imaging, it was
ecoming clearer in the early 1980s that 99mTc-
abeled perfusion tracers may in time replace 201Tl
for the clinical assessment of myocardial perfusion
(48,49). Significant developments were finally an-
nounced in 1984 by Jones et al. (50) of a new group
of 99mTc-labeled myocardial perfusion radiotracers,
he 99mTc isonitriles (51). After an intensive search
or the ideal 99mTc-isonitrile compound, 99mTc-
estamibi (also referred as RP-30) emerged with the
ost favorable biological and imaging characteris-
ics for clinical applications (Fig. 6) and was intro-
uced commercially in December 1990 after FDA
pproval (52–54). Compared with its other isoni-
rile predecessors, which showed a poor myocardial-
o-background activity ratio and high lung uptake,
99mTc-sestamibi exhibited a transient liver uptake
and subsequent rapid hepatobiliary excretion with
minimal lung uptake.
Only few weeks after the FDA approval of
99mTc-sestamibi, another 99mTc-labeled myocardial
erfusion imaging agent, 99mTc-teboroxime, also
obtained FDA approval (55). 99mTc-teboroxime is
Table 1. Potential Advantages of a 99mTc-Labeled Agent
Over 201Tl
1. The 140-keV photon energy of 99mTc, which is optimal for
standard gamma camera imaging, results in an improved
resolution due to less Compton scatter and less tissue
attenuation in the patient (compared with the low photon
energy of 68 to 80 keV for 201Tl).
2. The much shorter physical half-life of 99mTc (6 h vs. 73 h for
201Tl) and the better radiation dosimetry allow for the
administration of a 10 times higher dose of a 99mTc-labeled
agent compared with 201Tl. This yields higher quality images
with shorter acquisition time.
3. The overall higher count statistics of 99mTc allows for the
perfusion images to be obtained in an
electrocardiographically gated mode. Simultaneous
assessment of myocardial perfusion and LV function (global
and regional wall motion) can thus be obtained with a single
radiotracer injection.
4. It is also possible to perform ﬁrst-pass function studies (if the
initial lung transit is rapid enough) with a 99mTc-labeled
radiopharmaceutical agent.
5. Because 99mTc is constantly available from a molybdenum 99
generator in a nuclear medicine laboratory, special deliveries
from a distribution center or a commercial radiopharmacy are
not required. A 99mTc-labeled myocardial perfusion imaging
agent can thus be available almost 24 h a day, although
99Mo shortage in the United States has become a problem
recently (46,47).
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1277a member of the boronic acid adducts of technetium
dioxime complexes (BATO) with a neutral charge
and high lipophilicity. It is a freely diffusible tracer
with high extraction fraction over a wide range of
coronary blood flow rates (56), higher than 99mTc-
estamibi or 201Tl. However, the myocardial half-
Figure 6. Planar Myocardial Perfusion Images Obtained in the F
Department of Nuclear Medicine of Hotel-Dieu de Montréal Ho
(A) Stress and rest planar 201Tl images are shown (top row) from
and corresponding 99mTc-sestamibi (MIBI) images (bottom row).
multicenter trial phases II and III at Hotel-Dieu de Montréal Hosp
Nuclear Medicine; Dr. Francois Lemire, interventional cardiologist; Dr. P
medicine technologist on the team shown lying under the camera, Holife of 99mTc-teboroxime is approximately 9 min, twhich is a very narrow time window for optimal
myocardial perfusion imaging, particularly because
it takes between 1 and 2 min for the 99mTc-
teboroxime to clear the blood pool 5 to 6 min to
clear the liver. These imaging characteristics have
limited the clinical applications of 99mTc-
Group of Patients Injected With 99mTc-Sestamibi in 1985 at the
al
patient with 95% stenosis of the left anterior descending artery
Some of the personnel initially involved in the 99mTc-sestamibi
From left to right: Dr. Raymond Taillefer, Chief of the Department of
Costi, electrophysiologist; and Carole Benjamin, who was a nuclear
ieu de Montréal Hospital.irst
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1278However, with the introduction of new high-speed
SPECT cameras with high counting sensitivity and
new software that allows for fast image acquisition
protocols, it is possible that 99mTc-teboroxime may
e reintroduced to the clinical arena.
99mTc-tetrofosmin (also referred to as P53) was
the third FDA-approved 99mTc-labeled myocardial
erfusion agent to be released and made commercially
vailable after 99mTc-sestamibi and 99mTc-
teboroxime. 99mTc-tetrofosmin and 99mTc-sestamibi
show similar myocardial uptake, retention, blood
clearance kinetics, and lack of myocardial redistribu-
tion (57,58). However, the clearance of 99mTc-
tetrofosmin from both the liver and lung is faster than
that of 99mTc-sestamibi (58). These characteristics
may offer an interesting potential for decreasing the
overall time necessary to complete rest-stress SPECT
studies. The overall diagnostic accuracy of 99mTc-
tetrofosmin imaging in the detection of CAD is
similar to that of 201Tl and 99mTc-sestamibi (59).
Although many other 99mTc-labeled myocardial
erfusion imaging agents were investigated, 99mTc-
-NOET(N-ethoxyl-N-ethyl dithiocarbamato-
itrito) is the latest radiotracer that reached phase
II clinical trials but is not FDA approved for
linical use (60). 99mTc-N-NOET is a neutral
omplex that shows a significant myocardial redis-
ribution over time, similar to that of 201Tl. How-
ever, the relatively high percentage of lung uptake
seen on phase III clinical trial images, despite a
30-min delay after the injection of 99mTc-N-
OET, particularly in patients with a history of
moking, was identified as a drawback for its clinical
se. Moreover, the image quality obtained with
99mTc-N-NOET was graded as inferior to that of
201Tl (60), which became a discouraging factor for
its commercialization.
NEW APPLICATIONS IN ACUTE CLINICAL SETTINGS
AND GATED SPECT. The higher count rate achieved
ith both 99mTc-sestamibi and 99mTc-tetrofosmin
nd the lack of significant myocardial redistribution
llowed for new applications of these radiotracers in
cute clinical settings and for the assessment of
yocardial function. In the emergency department,
99mTc-labeled radiotracers can be administered im-
mediately before specific therapy is initiated and
imaging can be postponed until the patient’s clinical
condition is stabilized (61–64). Two new acute
indications for myocardial perfusion imaging have
emerged since the clinical introduction of 99mTc-
labeled radiotracers: evaluation of thrombolytic
therapy in patients with acute myocardial infarction
and detection of myocardial ischemia in patients bpresenting to the emergency department with spon-
taneous (acute) chest pain.
Gated SPECT significantly improved the speci-
ficity of interpretation of myocardial perfusion stud-
ies, allowing differentiation of soft-tissue attenuation
artifacts (breast or diaphragmatic) or physiological
apical thinning (59,65) from true perfusion defects.
Gated SPECT studies also allowed the determination
of LV ejection fraction, which, in concert with LV
volumes and myocardial perfusion defects, expanded
the role of SPECT from detection of coronary artery
stenosis to risk stratification (66,67) and assessment of
myocardial viability (68,69). Gated SPECT can also
improve the sensitivity of the test by identifying larger
perfusion defects on the end-diastolic frames of the
gated images. One advantage of electrocardiographic
gating of myocardial perfusion studies is to be able to
extract and analyze only the end-diastolic images from
the complete cardiac cycle images. This may result in
better image resolution by reducing the blurring effect of
cardiac motion and also by decreasing the partial volume
effect. Studies have confirmed that end-diastolic images
can detect more ischemic defects, especially in patients
with small hearts (mostly women) in whom ungated
images are more likely to miss or underevaluate the
presence of ischemia. Thus, gated SPECT (which also
applies to gated PET) provides the technology for
investigating myocardial function and perfusion at the
same setting and their summation for diagnosing CAD
and myocardial viability.
Transition from SPECT to PET myocardial perfusion
tracers: 82Rb and 13N-ammonia. PET flow agents can
e divided into freely diffusible tracers and soluble
icrospheres (70). The rapid physiological washout
f a freely diffusible tracer from the myocardium,
uch as 15O-water, gives one the ability to carry out
epeated studies in rapid sequence. However, the
istribution of such tracers usually does not give
linically meaningful images for visual interpreta-
ion. Rather, one must perform mathematical mod-
ling at each pixel to arrive at flow values at each
ixel (71,72). Such computations often produce
uite noisy images. An advantage of freely diffusible
racers, however, is that they do not depend on a
etabolic trapping mechanism—a mechanism that
ight change as a function of a changing metabolic
nvironment or pharmaceuticals.
The soluble radiolabeled microspheres are usually
asier to scan because the radioactivity is fixed in
lace for a reasonable length of time and therefore
ptimal counting statistics can be obtained. How-
ver, a potential disadvantage of the persistence of
inding is that it limits the ability to carry out rapid
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1279sequential studies, unless the radiotracer has an
ultrashort half-life, such as 82Rb, which reduces
radiation exposure to the patient. In addition, if
intracellular binding of the radiotracer is dependent
on a biochemical interaction, this could potentially
confound the flow measurement, particularly if this
interaction changes as a function of disease. How-
ever, most studies have shown that such a metabolic
effect on the extraction or retention of the radio-
tracer is only small and negligible for blood flow
measurements. 82Rb and 13N-ammonia fall into the
more microsphere-like flow tracers.
In experimental studies, myocardial uptake of
82Rb reflects absolute blood flows of as much as 2 to
3 ml/g/min; however, net uptake of 82Rb plateaus at
the hyperemic flows often achieved with pharma-
cological stress. Nonetheless, qualitative assessment
of relative 82Rb perfusion defects have correlated
well with those obtained from microspheres (73),
and in the clinical setting, such relative uptake
assessment has yielded both high sensitivity and
specificity for detecting CAD (74,75). Because of
its 10-min physical half-life, the use of 13N-
ammonia requires an on-site cyclotron, thus limit-
ing its use to a very limited number of sites. 82Rb,
produced by a portable generator, offers an inter-
esting alternative but is not ideal because of its very
long positron range, which decreases the spatial
resolution and has a lower myocardial extraction
than 13N-ammonia, potentially reducing the inten-
ity of the perfusion defects, which may represent
n obstacle for absolute quantification of MBF.
13N-ammonia is a valuable agent for assessing
either relative myocardial uptake or measuring ab-
solute MBF (16,76–79). For measurements of ab-
solute blood flow, dynamic acquisition from time of
injection is required, followed by applying 2- and
3-compartment kinetic models that incorporate
both extraction and retention rate constants (78–80).
Recently, commercially available software has been
introduced to compute absolute flow measurements
with 13N-ammonia in the clinical setting.
In search of the “ideal” clinical perfusion tracer: 18F-
uorine–labeled cardiac imaging agents? To be ideal
for clinical imaging, a myocardial perfusion tracer
must have high and rapid myocardial uptake fol-
lowed by long retention in myocytes (Table 2).
For 15 years, various radiolabeled analogs of
mitochondrial complex I inhibitors, including rote-
none, have been investigated in a variety of species
(81,82), and the most promising member of these
radiotracers, 18F-flurpiridaz, was recently intro-
duced to undergo clinical trials. The myocardialperfusion characteristics of 18F-flurpiridaz were
evaluated using contractile neonatal rat cardiomyo-
cytes in vitro and the biodistribution was assessed in
vivo in a mouse model (83). The results established
that 18F-flurpiridaz binds to mitochondrial complex
potently, has rapid uptake and slow washout from
ardiac myocytes, and has sustained uptake in the
eart of the mouse. In a subsequent publication,
issue biodistribution and first-pass extraction of
18F-flurpiridaz were evaluated in rat, rabbit, and
nonhuman primate models at rest with a reported
first-pass extraction fraction 90% (84). The re-
sults showed that myocardial uptake of 18F-
urpiridaz was significantly higher than that of
99mTc-sestamibi not only at normal MBF range in
rats but also at high MBF ranges (5 ml/min/g) in
isolated rabbit hearts, suggesting that 18F-
flurpiridaz may be less affected by the “roll-off”
phenomena commonly seen with SPECT imaging
agents such as 99mTc-sestamibi, 99mTc-tetrofosmin,
and 201Tl. This should result in improved detection
f multivessel disease and mild-to-moderate CAD,
specially with pharmacological intervention where
igher flow rates are seen. Moreover, cardiac per-
usion deficits produced as a “no-flow” region after
ermanent coronary ligation or an infarct region
fter coronary ligation and reperfusion were also
learly imaged with 18F-flurpiridaz (84). Myocar-
ial uptake of 18F-flurpiridaz was shown to be
stable for at least 1 h after injection, and there was
no significant myocardial redistribution.
Further pre-clinical studies with 18F-flurpiridaz
confirmed these findings during pharmacological
Table 2. Criteria for the “Ideal” PET Myocardial Perfusion
Imaging Radiotracer
1. High myocardial uptake with no or minimal myocardial
redistribution.
2. A high target-to-background ratio with low uptake in the
adjacent organs.
3. Linear relationship between radiotracer uptake and coronary
blood ﬂow: 5 ml/min/g (level seen with pharmacological
vasodilation); this requires a high ﬁrst-pass myocardial
extraction fraction and a subsequent very rapid blood
clearance.
4. Physical half-life that will allow enough time for adequate
image acquisition with both treadmill stress test and
pharmacological intervention.
5. Positron energy that will provide better image quality and
high diagnostic accuracy for the detection of CAD.
6. Quantiﬁcation of absolute MBF, enabling identiﬁcation of
diffuse, multivessel, or balanced CAD.
7. Appropriate radiation safety proﬁle.
8. Availability as unit dose, preferably labeled with 18F because
of its favorable positron physical characteristics and physical
half-life of 109 min.stress conditions. In an experimental pig model of
r
t
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1280transient constriction of the left anterior descending
coronary artery, 18F-flurpiridaz was compared with
13N-ammonia PET and was further validated with
microspheres at rest and during pharmacological va-
sodilation (85). Compared with 13N-ammonia, 18F-
Figure 7. Representative Examples of Normal and Abnormal 18F
(A) Consecutive tomograms of paired stress (top row) and rest (bo
myocardial regions. (B) Paired stress (top row) and rest (bottom ro
3 coronary artery vascular territories associated with transient ischemicflurpiridaz showed higher activity ratios between the
myocardium and blood, liver, and lungs. Regional
MBF assessed with 18F-flurpiridaz showed good cor-
elation (r  0.88, slope  0.84) and agreement with
hat measured with radioactive microspheres over a wide
rpiridaz PET Myocardial Perfusion Images
row) images show normal distribution of the radiotracer in all
mages show extensive reversible regional perfusion defects in all-Flu
ttom
w) icavity dilation.
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1281flow range from 0.1 to 3.0 ml · min1· g1. The extent
f defects induced by left anterior descending coronary
rtery constriction measured by 18F-flurpiridaz and mi-
crospheres also correlated closely (85).
The high spatial resolution of PET imaging,
along with high target-to-background ratios
achieved with 18F-flurpiridaz, allows the acquisition
f very high-quality electrocardiographic-gated
ET images in both animal and human studies.
nitial studies in humans have shown a very good
iagnostic accuracy in detection of significant CAD
Fig. 7). Regarding its potential for quantification
f absolute MBF and MFR, in an experimental
tudy, measurement of the standardized uptake
alue obtained at 5 to 10 min after 18F-flurpiridaz
ntravenous injection showed a linear correlation
ith adenosine hyperemia MBF as quantified by
adiolabeled microspheres (86). Further studies in
umans will be needed to evaluate the clinical
easibility and diagnostic accuracy of this method,
articularly in patients with multivessel CAD.
The safety and toxicity of 18F-flurpiridaz have
een investigated in both animals and humans.
18F-flurpiridaz can be synthesized by a 1-step direct
fluorination in a radiopharmacy, using an auto-
mated synthesis unit. In phase I and II studies, no
significant adverse events were reported. Further-
more, 181F-flurpiridaz has been shown to be effec-
tive with both exercise and pharmacological stress
tests (87). Initial clinical experience with this new
agent showed high-resolution myocardial perfusion
images (Fig. 7) with acceptable radiodosimetry and
assessment of LV function.
The phase III clinical trial of 18F-flurpiridaz in
atients with CAD is near completion. The biolog-
cal and imaging characteristics of 18F-flurpiridaz
represents a significant improvement over currently
available SPECT and PET myocardial perfusion
tracers. It fulfills almost all the major properties of
an “ideal” PET myocardial perfusion imaging ra-N Engl J Med 1973;288:809–12. B, Wagner HN. Clow positron range, longer physical and biological
half-lives, a very good correlation between its myo-
cardial uptake and coronary blood flow, a high
target-to-background ratio, no significant myocar-
dial redistribution, a favorable safety profile, and
availability in unit doses from regional medical
cyclotrons. Moreover, the 2-h half-life of 18F per-
mits same-day rest-stress myocardial perfusion
studies.
Will There Be Another Quantum Leap in the Field?
In the early years of myocardial perfusion imaging,
many of the important discoveries related to coronary
artery physiology and myocardial uptake and retention
of the radiotracers within cardiomyocytes in relation
to biochemical interactions and metabolic distur-
bances that may be altered with ischemia, infarction,
and LV remodeling. In the present decade, the intro-
duction of advanced digital computers for extracting
small biologically relevant signals from background
noise and for performing statistical sorting, has
opened the way to detailed quantifiable measures and
studies of myocardial perfusion in health and disease,
including microvascular diseases, acute coronary syn-
dromes, and myopathic disorders. Beyond detection
of CAD, the prognostic information provided by
nuclear myocardial perfusion imaging propelled the
field forward as a critical component for patient
management despite obstacles in the health mainte-
nance organization era in the 1990s and more recent
concerns of ionizing radiation and cost (88). These
advances have removed the lack of clarity from the
sphere of nuclear imaging to that of molecular and
hybrid imaging of biology, physiology, and
morphology.
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